Author Archives: Marta Figueiredo PhD

A two-dose rituximab regimen is as safe and works as well as the standard four doses in inducing remission in adults with severe granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), according to a review study. While these findings support the current use of either regimen in clinical practice…

Vasculitis UK has awarded a total of £200,000 (about $283,000) in four grants to research projects mostly focused on the development of new therapeutic approaches and biomarkers for ANCA-associated vasculitis (AAV) and other vasculitis. All grants, each about £50,000 (about $70,800), were given to researchers at academic institutions…

People with rare disorders have a worse healthcare experience than those affected by chronic diseases, according to the results of an international survey conducted by Eurordis-Rare Diseases Europe. Indeed, rare disease patients overall give their healthcare experience a medium-low rating, of 2.5 on a scale of 1 to 5,…

The first wave of COVID-19 in Europe severely disrupted access to care and raised stress and anxiety in people with rare diseases, negatively affecting their health and well-being, according to a survey conducted by Eurordis-Rare Diseases Europe. “People living with rare diseases in Europe have found themselves caught as collateral…

The European Medicines Agency (EMA) has agreed to review Vifor Pharma and ChemoCentryx’s application requesting the approval of avacopan to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the companies announced in a press release. GPA and MPA are two types of…

High blood levels of FCRL5 — a protein mainly found in certain B-cells, a type of immune cell — are linked with a greater likelihood of achieving and maintaining a complete response to rituximab in people with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA),…

Mycophenolate mofetil (MMF) may be a safe and effective alternative to the standard induction therapy cyclophosphamide in certain ANCA-associated vasculitis (AAV) patients, a review study reports. Based on the data, researchers recommend that MMF be used in patients with autoantibodies against myeloperoxidase (MPO), non-life-threatening disease, and those…

Lung involvement increases the risk for both induction therapy resistance and disease relapse in ANCA-associated vasculitis (AAV) patients with autoantibodies against myeloperoxidase, a Chinese study suggests. High levels of creatinine was also found to be a risk factor for treatment resistance. These findings, while needing further confirmation,…

ChemoCentryx has secured a credit facility of up to $100 million from Hercules Capital to support the upcoming costs of its new drug application (NDA) for avacopan, its investigational treatment for ANCA-associated vasculitis (AAV), and the therapy’s commercial launch, if approved. The $100 million credit will be divided into…

Mitochondrial DNA (mtDNA) — DNA specific to mitochondria, the cell’s powerhouses — may be used as a urinary biomarker of kidney damage in people with ANCA-associated vasculitis (AAV), according to a Chinese study. The study, “Urinary mitochondrial DNA is a useful biomarker for assessing kidney injury…